A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis
Leptomeningeal Carcinomatosis|Non-small Cell Lung Cancer
DRUG: Erlotinib
Overall survival, 1 year
Cytology negative conversion rate, 1 month, 2 months, 3 months, 4 months|Neurologic symptom improvement, 1 month, 2 months, 3 months, 4 months|Response rate (extra-cranial disease), 2 months, 4 months|Response rate (brain), 2 months, 4 months|Quality of life, 1 month, 2 months, 3 months, 4 months|Toxicities, 1 month, 2 months, 3 months, 4 months|Prognostic factors, N-A
To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis